Development by Boehringer Ingelheim was halted in October 2010, following a negative evaluation by the US Food and Drug Administration (FDA).Spiegel online: Pharmakonzern stoppt Lustpille für die Frau, 8 October 2010 (in German) The rights to the drug were then transferred to Sprout Pharmaceuticals, which achieved approval of the drug by the US FDA in August 2015.
